Montreal, Quebec – September 23, 2019 – Emovi, Inc. announced today they have received the support of the Quebec government with financial assistance of $4.8 million bringing their total funding for 2019 over $20 million. The investment is part of the BioMed Propulsion program administered by Investissement Québec and will be used to expand Emovi’s KneeKG into the US market.
KneeKG is the first device that enables doctors to accurately assess patients’ knees in 3D while the patient is moving and weight-bearing. In contrast to static information provided by X-ray and magnetic resonance imaging (MRI), KneeKG quickly identifies the dynamic function of impaired knees allowing healthcare professionals to determine the most strategic treatment plan to restore the knee. KneeKG is revolutionizing knee assessment techniques and is more efficient than the current methodology, a process of elimination. By providing doctors with technical information that has a higher correlation to symptoms and at a fraction of the cost of high-tech scans such as MRIs, the KneeKG allows health care professionals to significantly improve patients’ quality of life while reducing pain and functional limitations.
“Knee pain is the second most common source of chronic pain in the United States, an affliction affecting one-third of Americans at some time or another,” said Emovi CEO, Michelle Laflamme. “These funds will allow us to continue our momentum and execute our vision more rapidly as we grow our team, scale our operations and focus our efforts on restoring patients’ quality of life.”